Cargando…
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
SIMPLE SUMMARY: Genomic instability (GI) caused by homologous repair deficiency (HRD) is a novel highly clinically relevant biomarker that cannot only identify patients suffering from high-grade serous ovarian cancer that may benefit from poly-ADP ribose polymerase (PARP) inhibitors but also helps i...
Autores principales: | Willing, Eva-Maria, Vollbrecht, Claudia, Vössing, Christine, Weist, Peggy, Schallenberg, Simon, Herbst, Johanna M., Schatz, Stefanie, Jóri, Balázs, Bataillon, Guillaume, Harter, Philipp, Salutari, Vanda, Martin, Antonio Gonzáles, Vergote, Ignace, Colombo, Nicoletta, Roeper, Julia, Berg, Tobias, Berger, Regina, Kah, Bettina, Noettrup, Trine Jakobi, Falk, Markus, Arndt, Kathrin, Polten, Andreas, Ray-Coquard, Isabelle, Selzam, Franziska, Pirngruber, Judith, Schmidt, Stefanie, Hummel, Michael, Tiemann, Markus, Horst, David, Sehouli, Jalid, Pujade-Lauraine, Eric, Tiemann, Katharina, Braicu, Elena Ioana, Heukamp, Lukas C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341077/ https://www.ncbi.nlm.nih.gov/pubmed/37444554 http://dx.doi.org/10.3390/cancers15133445 |
Ejemplares similares
-
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
por: Jóri, Balázs, et al.
Publicado: (2023) -
Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO
por: Heublein, Sabine, et al.
Publicado: (2023) -
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy
por: Jóri, Balázs, et al.
Publicado: (2022) -
TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinib
por: Roeper, Julia, et al.
Publicado: (2022) -
Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
por: Jóri, Balázs, et al.
Publicado: (2021)